Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11855010 | 1.00 | CA1 (0.39) | CA1CA2CA7CYP2D6CA12 | |
| SCHEMBL4671957 | 1.00 | CA1 (0.39) | CA1CA2CA7CYP2D6CA12 | |
| SCHEMBL8030378 | 0.86 | HTT (0.40) | CA1CA2CA7CYP2D6CA12 | |
| SCHEMBL1845280 | 0.86 | HTT (0.40) | CA1CA2CA7CYP2D6CA12 | |
| SCHEMBL8028869 | 0.86 | HTT (0.40) | CA1CA2CA7CYP2D6CA12 | |
| SCHEMBL19407016 | 0.86 | HTT (0.40) | CA1CA2CA7CYP2D6CA12 | |
| SCHEMBL3347516 | 0.81 | NOS1 (0.37) | CA1CA2CA7CYP2D6CA12 | |
| SCHEMBL9094607 | 0.81 | NOS1 (0.37) | CA1CA2CA7CYP2D6CA12 | |
| SCHEMBL305050 | 0.81 | TP53 (0.38) | CA1CA2CA7CYP2D6CA12 | |
| SCHEMBL1332536 | 0.81 | TP53 (0.38) | CA1CA2CA7CYP2D6CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025045233-A1 | MACROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF | 劲方医药科技(上海)股份有限公司 | 2025-03-06 | — | — | WO | disclosed |
| EP-3723745-B1 | PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA AS (DK) | 2024-06-19 | — | — | EP | disclosed |
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-08-22 | — | — | US | disclosed |
| US-11147788-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2021-10-19 | — | — | US | disclosed |
| US-20190183834-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190183833-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA APS | 2019-06-20 | — | — | US | disclosed |
| EP-1923386-A2 | Carbamate caspase inhibitors and uses thereof | Vertex Pharmceuticals Incorporated (US) | 2008-05-21 | — | — | EP | disclosed |
| EP-1268425-B1 | CARBAMATE CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2008-01-23 | — | — | EP | disclosed |
| US-7074782-B2 | Carbamate caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-07-11 | — | — | US | disclosed |
| US-20040053920-A1 | Carbamate caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-03-18 | — | — | US | disclosed |
| US-6689784-B2 | CONTROLLING CELL APOPTOSIS | VERTEX PHARMACEUTICALS INCORPORATED | 2004-02-10 | — | — | US | disclosed |
| EP-1268425-A2 | CARBAMATE CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020028803-A1 | Carbamate caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2002-03-07 | — | — | US | disclosed |
| WO-2001072707-A2 | CARBAMATE CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028803-A1 | Carbamate caspase inhibitors and uses thereof | CASP1, CASP2, CASP3 | CA1 38/4885CA2 44/4885CA7 90/4885 |
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | CA1 1058/4885CA2 211/4885CA7 2032/4885 |
| US-20190183834-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | CA1 1058/4885CA2 211/4885CA7 2032/4885 |
| US-11147788-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | CA1 1058/4885CA2 211/4885CA7 2032/4885 |
| US-20040053920-A1 | Carbamate caspase inhibitors and uses thereof | CASP1, CASP2, CASP3 | CA1 38/4885CA2 44/4885CA7 90/4885 |
| US-20190183833-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | CA1 1058/4885CA2 211/4885CA7 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.